GH Research (NASDAQ:GHRS) Stock Price Up 3.3% – Time to Buy?

Shares of GH Research PLC (NASDAQ:GHRS) rose 3.3% on Monday . The stock traded as high as $9.60 and last traded at $9.39. Approximately 30,164 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 79,384 shares. The stock had previously closed at $9.09.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. JMP Securities restated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research note on Wednesday, September 4th. Canaccord Genuity Group decreased their price target on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Thursday, September 5th.

GH Research Stock Up 1.5 %

The firm has a fifty day moving average of $7.82 and a 200-day moving average of $10.33. The stock has a market capitalization of $499.99 million, a price-to-earnings ratio of -12.16 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, research analysts forecast that GH Research PLC will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP raised its stake in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the quarter. GH Research makes up 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent filing with the Securities & Exchange Commission. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).